ValiRx PLC Update on Recent Presentations

TIDMVAL

ValiRx PLC

13 October 2016

VALIRX PLC

("ValiRx", "the Company" or "the Group")

UPDATE ON RECENT PRESENTATIONS

London, UK., 13 October 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, is pleased to provide an update on recent presentations.

A presentation, in the form of a poster, was given by the Company and its Principle Clinical Investigator at the prestigious European Society for Medical Oncology ("ESMO") Conference on Monday, 10 October 2016 in Copenhagen.

The presentation provided data from the Company's "First-in-human (FIH) phase I/II, dose escalation and pharmacokinetic (PK) study to show the safety and tolerability of VAL201 in patients with advanced prostate cancer and other advanced solid tumours."

The poster showed early indications of efficacy in advanced prostate cancer with no drug-related serious adverse events recorded, as was previously announced via RNS on 13 September 2016. The study continues with expansion into other tumour types. An Endometriosis trial is also being planned.

A link to the poster will shortly be made available on the 'News' section of the ValiRx website: www.valirx.com.

The Company also recently gave presentations to investors at the Shares Investor Evening in Edinburgh on Wednesday, 5 October 2016 and at the Proactive Investor One2One Forum in Mayfair, London on Thursday, 6 October 2016.

A video link to Dr George Morris, COO's presentation in Edinburgh is also available on the 'News/Video' section of the ValiRx's website.

All of these events were well attended.

ValiRx intends to continue presenting clinical data at various international conferences in the future and it will update the market on progress regularly.

Dr Satu Vainikka, CEO, commented:

"We are delighted with the enthusiastic reception from the international biopharma community over our progress in oncology therapeutic development in this exciting new personalized field of medicine".

"We are extremely pleased with the results of our clinical trials and of the preliminary results on endometriosis. We look forward to updating the market on developments in due course".

*** ENDS ***

For more information, please contact:

 
 ValiRx Plc                                 Tel: +44 (0) 20 
                                             3008 4416 
                                             www.valirx.com 
 Dr Satu Vainikka, Chief Executive          Tel: +44 (0) 20 
                                             3008 4416 
 Tarquin Edwards, Head of Communications.   Tel: [phone] 
                                             458 364 
                                             [e-mail] 
 Mark Treharne, Corporate Development       Tel: [phone] 
  Manager                                    564 686 
                                             [e-mail] 
 
 

Notes for Editors

ValiRx Plc

ValiRx is a biotechnology oncology focussed company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's three classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAMTBBTMBIBTLF

(END) Dow Jones Newswires

October 13, 2016 02:00 ET (06:00 GMT)